118010-84-7

Basic information

• Product Name: Acetic acid, chloro[(4-fluorophenyl)hydrazono]-, methyl ester
• CAS NO: 118010-84-7
• Molecular Formula: C9H8ClFN2O2
• Molecular Weight: 230.626
• Mol File: 118010-84-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Acetic acid, chloro[(4-fluorophenyl)hydrazono]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, chloro[(4-fluorophenyl)hydrazono]-, methyl ester(118010-84-7)
• EPA Substance Registry System: Acetic acid, chloro[(4-fluorophenyl)hydrazono]-, methyl ester(118010-84-7)

Safety Data

• Hazardous Substances Data: 118010-84-7(Hazardous Substances Data)

Upstream product

• 4755-81-1 methyl 2-chloroacetoacetate 
• 371-40-4 4-fluoroaniline 
• 20893-71-4 4-fluorophenyldiazonium chloride 

Downstream Products

• 1196967-07-3 C₁₈H₁₄FN₃O₃ 
• 1196967-06-2 C₁₈H₁₄FN₃O₃ 
• 1196966-95-6 C₁₉H₁₅FN₂O₄ 
• 1196966-94-5 C₁₉H₁₅FN₂O₄ 
• 1196967-18-6 C₁₈H₁₅FN₂O₂ 
• 235789-27-2 methyl 1-(4-fluorophenyl)-5-phenylpyrazole-3-carboxylate 
• 1090363-10-2 1-(4-fluorophenyl)-3-methoxycarbonyl-5-methyl-1,2,4-triazole 

Relevant articles and documents

Development of Radiolabeled Ligands Targeting the Glutamate Binding Site of the N-Methyl-d-aspartate Receptor as Potential Imaging Agents for Brain

Abnormal activity of various N-methyl-d-aspartate receptor (NMDAR) subtypes has been implicated in a wide variety of neurological disorders such as Alzheimer's disease, schizophrenia, and epilepsy. Imaging agents for PET and SPECT that target NMDARs in a subtype-selective fashion may enable better characterization of those disorders and enhance drug development. On the basis of a pyrazoline derivative that demonstrated neuroprotective effects in vivo, we synthesized a series of para-substituted analogues and measured their affinities to various NMDAR subtypes. Compounds 4a-c and 4e showed greater, nanomolar affinity for the GluN1/2A subtype versus GluN1/2B. Dicarbomethoxy (pro-drug) analogues of [124/125I]4d and [11C]4e (i.e., [124/125I]11d and [11C]11e) were generated and tested for NMDAR binding specificity in ex vivo autoradiography and brain biodistribution studies. Although NMDAR-specific binding could be demonstrated for [125I]11d and [11C]11e through autoradiography and biodistribution studies, imaging of neither [124I]11d nor [11C]11e could demonstrate brain penetration sufficient for detection by PET.

Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: Discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl- benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia

In light of accumulating evidence that aggressive LDL-lowering therapy may offer increased protection against coronary heart disease, we undertook the design and synthesis of a novel series of HMG-CoA reductase inhibitors based upon a substituted pyrazole template. Optimizing this series using both structure-based design and molecular property considerations afforded a class of highly efficacious and hepatoselective inhibitors resulting in the identification of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzyl- carbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxy-heptanoic (PF-3052334) as a candidate for the treatment of hypercholesterolemia.

HETEROCYCLES FROM NITRILE IMINES. PART I. 1,2,3,4-TETRAHYDRO-1,2,4,5-TETRAZINES

The interaction between ketohydrazones and nitrile imines provides a new and direct synthetic route to 1,2,3,4-tetrahydro-1,2,4,5-tetrazines.Elemental analysis and spectral data are consistent with the assigned tetrazine ring system.